International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors

Autores
Dubocovich, Margarita L.; Delagrange, Philippe; Krause, Diana N.; Sugden, David; Cardinali, Daniel Pedro; Olcese, James
Año de publicación
2010
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The hormone melatonin (5-methoxy-N-acetyltryptamine) is synthesized primarily in the pineal gland and retina, and in several peripheral tissues and organs. In the circulation, the concentration of melatonin follows a circadian rhythm, with high levels at night providing timing cues to target tissues endowed with melatonin receptors. Melatonin receptors receive and translate melatonin's message to influence daily and seasonal rhythms of physiology and behavior. The melatonin message is translated through activation of two G protein-coupled receptors, MT1 and MT2, that are potential therapeutic targets in disorders ranging from insomnia and circadian sleep disorders to depression, cardiovascular diseases, and cancer. This review summarizes the steps taken since melatonin's discovery by Aaron Lerner in 1958 to functionally characterize, clone, and localize receptors in mammalian tissues. The pharmacological and molecular properties of the receptors are described as well as current efforts to discover and develop ligands for treatment of a number of illnesses, including sleep disorders, depression, and cancer.
Fil: Dubocovich, Margarita L.. Northwestern University; Estados Unidos. Jacobs School Of Medicine And Biomedical Sciences; Estados Unidos
Fil: Delagrange, Philippe. Institut de Recherches Servier; Francia
Fil: Krause, Diana N.. University of California; Estados Unidos
Fil: Sugden, David. King's College London; Reino Unido
Fil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina
Fil: Olcese, James. Florida State University; Estados Unidos
Materia
MELATONINA
NOMENCLATURA
FARMACOLOGIA
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/190895
Acceder
id CONICETDig_12b892b69de3c9146781ca4ae78eeee6
oai_identifier_str oai:ri.conicet.gov.ar:11336/190895
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptorsDubocovich, Margarita L.Delagrange, PhilippeKrause, Diana N.Sugden, DavidCardinali, Daniel PedroOlcese, JamesMELATONINANOMENCLATURAFARMACOLOGIAhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3The hormone melatonin (5-methoxy-N-acetyltryptamine) is synthesized primarily in the pineal gland and retina, and in several peripheral tissues and organs. In the circulation, the concentration of melatonin follows a circadian rhythm, with high levels at night providing timing cues to target tissues endowed with melatonin receptors. Melatonin receptors receive and translate melatonin's message to influence daily and seasonal rhythms of physiology and behavior. The melatonin message is translated through activation of two G protein-coupled receptors, MT1 and MT2, that are potential therapeutic targets in disorders ranging from insomnia and circadian sleep disorders to depression, cardiovascular diseases, and cancer. This review summarizes the steps taken since melatonin's discovery by Aaron Lerner in 1958 to functionally characterize, clone, and localize receptors in mammalian tissues. The pharmacological and molecular properties of the receptors are described as well as current efforts to discover and develop ligands for treatment of a number of illnesses, including sleep disorders, depression, and cancer.Fil: Dubocovich, Margarita L.. Northwestern University; Estados Unidos. Jacobs School Of Medicine And Biomedical Sciences; Estados UnidosFil: Delagrange, Philippe. Institut de Recherches Servier; FranciaFil: Krause, Diana N.. University of California; Estados UnidosFil: Sugden, David. King's College London; Reino UnidoFil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; ArgentinaFil: Olcese, James. Florida State University; Estados UnidosAmerican Society for Pharmacology and Experimental Therapeutics2010-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/190895Dubocovich, Margarita L.; Delagrange, Philippe; Krause, Diana N.; Sugden, David; Cardinali, Daniel Pedro; et al.; International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors; American Society for Pharmacology and Experimental Therapeutics; Pharmacological Reviews; 62; 3; 9-2010; 343-3800031-6997CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://pharmrev.aspetjournals.org/content/62/3/343info:eu-repo/semantics/altIdentifier/doi/10.1124/pr.110.002832info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T15:18:58Zoai:ri.conicet.gov.ar:11336/190895instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 15:18:58.772CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors
title International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors
spellingShingle International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors
Dubocovich, Margarita L.
MELATONINA
NOMENCLATURA
FARMACOLOGIA
title_short International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors
title_full International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors
title_fullStr International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors
title_full_unstemmed International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors
title_sort International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors
dc.creator.none.fl_str_mv Dubocovich, Margarita L.
Delagrange, Philippe
Krause, Diana N.
Sugden, David
Cardinali, Daniel Pedro
Olcese, James
author Dubocovich, Margarita L.
author_facet Dubocovich, Margarita L.
Delagrange, Philippe
Krause, Diana N.
Sugden, David
Cardinali, Daniel Pedro
Olcese, James
author_role author
author2 Delagrange, Philippe
Krause, Diana N.
Sugden, David
Cardinali, Daniel Pedro
Olcese, James
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv MELATONINA
NOMENCLATURA
FARMACOLOGIA
topic MELATONINA
NOMENCLATURA
FARMACOLOGIA
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The hormone melatonin (5-methoxy-N-acetyltryptamine) is synthesized primarily in the pineal gland and retina, and in several peripheral tissues and organs. In the circulation, the concentration of melatonin follows a circadian rhythm, with high levels at night providing timing cues to target tissues endowed with melatonin receptors. Melatonin receptors receive and translate melatonin's message to influence daily and seasonal rhythms of physiology and behavior. The melatonin message is translated through activation of two G protein-coupled receptors, MT1 and MT2, that are potential therapeutic targets in disorders ranging from insomnia and circadian sleep disorders to depression, cardiovascular diseases, and cancer. This review summarizes the steps taken since melatonin's discovery by Aaron Lerner in 1958 to functionally characterize, clone, and localize receptors in mammalian tissues. The pharmacological and molecular properties of the receptors are described as well as current efforts to discover and develop ligands for treatment of a number of illnesses, including sleep disorders, depression, and cancer.
Fil: Dubocovich, Margarita L.. Northwestern University; Estados Unidos. Jacobs School Of Medicine And Biomedical Sciences; Estados Unidos
Fil: Delagrange, Philippe. Institut de Recherches Servier; Francia
Fil: Krause, Diana N.. University of California; Estados Unidos
Fil: Sugden, David. King's College London; Reino Unido
Fil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina
Fil: Olcese, James. Florida State University; Estados Unidos
description The hormone melatonin (5-methoxy-N-acetyltryptamine) is synthesized primarily in the pineal gland and retina, and in several peripheral tissues and organs. In the circulation, the concentration of melatonin follows a circadian rhythm, with high levels at night providing timing cues to target tissues endowed with melatonin receptors. Melatonin receptors receive and translate melatonin's message to influence daily and seasonal rhythms of physiology and behavior. The melatonin message is translated through activation of two G protein-coupled receptors, MT1 and MT2, that are potential therapeutic targets in disorders ranging from insomnia and circadian sleep disorders to depression, cardiovascular diseases, and cancer. This review summarizes the steps taken since melatonin's discovery by Aaron Lerner in 1958 to functionally characterize, clone, and localize receptors in mammalian tissues. The pharmacological and molecular properties of the receptors are described as well as current efforts to discover and develop ligands for treatment of a number of illnesses, including sleep disorders, depression, and cancer.
publishDate 2010
dc.date.none.fl_str_mv 2010-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/190895
Dubocovich, Margarita L.; Delagrange, Philippe; Krause, Diana N.; Sugden, David; Cardinali, Daniel Pedro; et al.; International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors; American Society for Pharmacology and Experimental Therapeutics; Pharmacological Reviews; 62; 3; 9-2010; 343-380
0031-6997
CONICET Digital
CONICET
url http://hdl.handle.net/11336/190895
identifier_str_mv Dubocovich, Margarita L.; Delagrange, Philippe; Krause, Diana N.; Sugden, David; Cardinali, Daniel Pedro; et al.; International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors; American Society for Pharmacology and Experimental Therapeutics; Pharmacological Reviews; 62; 3; 9-2010; 343-380
0031-6997
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://pharmrev.aspetjournals.org/content/62/3/343
info:eu-repo/semantics/altIdentifier/doi/10.1124/pr.110.002832
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv American Society for Pharmacology and Experimental Therapeutics
publisher.none.fl_str_mv American Society for Pharmacology and Experimental Therapeutics
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846083338621681664
score 13.22299

Publicaciones similares